Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD). [Phase 1]

View source ↗

Summary

Phase 1 study in idiopathic pulmonary fibrosis assessed safety, tolerability, and pharmacokinetics of a monoclonal antibody. The trial is completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Unspecified monoclonal antibody

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED | Results posted: 2025-08-14